<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02517749</url>
  </required_header>
  <id_info>
    <org_study_id>RJ115/N175</org_study_id>
    <nct_id>NCT02517749</nct_id>
  </id_info>
  <brief_title>Out Patient Talc Slurry Via Indwelling Pleural Catheter for Malignant Pleural Effusion Vs Usual Inpatient Management</brief_title>
  <acronym>OPTIMUM</acronym>
  <official_title>Randomised Controlled Trial Comparing Outpatient Management of Malignant Pleural Effusion Via an Indwelling Pleural Catheter and Talc Pleurodesis Versus Standard Inpatient Management in Improving Health Related Quality of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CareFusion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Guy's and St Thomas' NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicentre randomised controlled trial evaluating global health related quality of
      life outcomes in patients with malignant pleural effusions. Patients will be randomised to
      receive either chest drain and talc pleurodesis or indwelling pleural catheter and talc
      pleurodesis. Patients will be followed up for 3 months post intervention
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global health-related quality of life</measure>
    <time_frame>30 days</time_frame>
    <description>Global health related quality of life as measured by EORTC QLQ-C30</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global health-related quality of life</measure>
    <time_frame>60 and 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pleurodesis failure rate</measure>
    <time_frame>30, 60 and 90 days</time_frame>
    <description>Subsequent pleural intervention required on same side as pleurodesis
Chest X-ray opacification greater than 25% on side of intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in symptoms of pain and breathlessness</measure>
    <time_frame>30, 60 and 90 days</time_frame>
    <description>Medical Research Council (MRC) dyspnoea scale 100mm Visual Analog Scale for pain and breathlessness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication rate</measure>
    <time_frame>Day 7, 14, 30, 60 and 90</time_frame>
    <description>Clinical review and adverse event documentation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">142</enrollment>
  <condition>Pleural Effusion, Malignant</condition>
  <arm_group>
    <arm_group_label>Usual Care Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will be managed as per the British Thoracic Society guideline for management of malignant pleural effusions. They will undergo chest tube insertion and undergo Talc pleurodesis with 4g of SteriTalc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Indwelling Pleural Catheter Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will undergo Indwelling Pleural Catheter (IPC) insertion. This will be inserted as per standard practice. They will undergo Talc pleurodesis via the IPC with 4g SteriTalc</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Chest Drain Insertion and Talc Pleurodesis</intervention_name>
    <arm_group_label>Usual Care Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Indwelling Pleural Catheter Insertion and Talc Pleurodesis</intervention_name>
    <arm_group_label>Indwelling Pleural Catheter Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of malignant pleural effusion

          2. WHO performance status 2 or less unless performance status is impaired by presence of
             effusion and likely to significantly improve with drainage

          3. Expected survival greater than 3 months

        Exclusion Criteria:

          1. Age less than 18 years old

          2. Pregnant or lactating

          3. Known allergy to Talc or Lignocaine

          4. Lack of symptomatic relief from effusion drainage

          5. At least twice weekly drainage cannot be undertaken

          6. Lymphoma or small cell carcinoma except*:

               1. Failure of chemotherapy

               2. Deemed for palliative management

          7. Non malignant effusions

          8. Loculated pleural effusion

          9. Unable to provide written informed consent to trial participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>Great Maze Pond</city>
        <state>London</state>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Peel</last_name>
      <phone>02071885736</phone>
      <email>joanna.peel@gstt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Liju Ahmed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2015</study_first_submitted>
  <study_first_submitted_qc>August 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2015</study_first_posted>
  <last_update_submitted>September 19, 2016</last_update_submitted>
  <last_update_submitted_qc>September 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pleural Effusion</mesh_term>
    <mesh_term>Pleural Effusion, Malignant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

